Your browser doesn't support javascript.
loading
Increasing the time of exposure to aerosol measles vaccine elicits an immune response equivalent to that seen in 9-month-old Mexican children given the same dose subcutaneously.
Wong-Chew, Rosa María; García-León, Miguel Leonardo; Espinosa-Torres Torrija, Bogart; Hernández-Pérez, Brenda; Cardiel-Marmolejo, Lino E; Beeler, Judy A; Audet, Susette; Santos-Preciado, José Ignacio.
Afiliação
  • Wong-Chew RM; Facultad de Medicina, Departamento de Medicina Experimental, Universidad Nacional Autónoma de México. rmwong@unam.mx
J Infect Dis ; 204(3): 426-32, 2011 Aug 01.
Article em En | MEDLINE | ID: mdl-21742842
ABSTRACT

BACKGROUND:

A 30-second aerosol measles vaccination successfully primes children 12 months of age and older but is poorly immunogenic when given to 9-month-old children. We examined the immune responses when increasing the duration to aerosol exposure in 9-month-olds.

METHODS:

One hundred and thirteen healthy 9-month-old children from Mexico City were enrolled; 58 received aerosol EZ measles vaccine for 2.5 minutes and 55 subcutaneously. Measles-specific neutralizing antibodies and cellular responses were measured before and at 3 and 6 months postimmunization.

RESULTS:

Adaptive immunity was induced in 97% after aerosol and 98% after subcutaneous administration. Seroconversion rates and GMCs were 95% and 373 mIU/mL (95% confidence interval [CI], 441-843) following aerosol vaccination and 91% and 306 mIU/mL (95% CI, 367-597) after subcutaneous administration at 3 months. The percentage of children with a measles-specific stimulation index ≥3 was 45% and 60% in the aerosol versus 55% and 59% in the subcutaneous group at 3 and 6 months, respectively. CD8 memory cell frequencies were higher in the aerosol group at 3 months compared with the subcutaneous group. Adverse reactions were comparable in both groups.

CONCLUSIONS:

Increasing exposure time to aerosol measles vaccine elicits immune responses that are comparable to those seen when an equivalent dose is administered by the subcutaneous route in 9-month-old infants.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacina contra Sarampo / Vacinação / Anticorpos Antivirais Tipo de estudo: Clinical_trials Limite: Female / Humans / Infant / Male País como assunto: Mexico Idioma: En Ano de publicação: 2011 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacina contra Sarampo / Vacinação / Anticorpos Antivirais Tipo de estudo: Clinical_trials Limite: Female / Humans / Infant / Male País como assunto: Mexico Idioma: En Ano de publicação: 2011 Tipo de documento: Article